The Advisory Board assists the APSA Board of Directors and President as they plan significant APSA initiatives and objectives. Advisory Board members advise and consult APSA leaders, sharing their experiences and helping APSA better accomplish its goals.
Dr. Richard B. Gaynor, MD is vice president, clinical development and medical affairs at Lilly. He is a physician in internal medicine, hematology and medical oncology.
Before Lilly, Dr. Gaynor was a professor of medicine and microbiology at the University of Texas Southwestern Medical Center (UTSW) in Dallas. He was chief of the Division of Hematology and Oncology at UTSW and director of the Harold C. Simmons Comprehensive Cancer Center. He served as the Lisa K. Simmons distinguished chair in comprehensive oncology. He also served on numerous NIH advisory committees and was elected to both the American Society of Clinical Investigation and Association of American Physicians.
Dr. Gaynor participated on the editorial board of several scientific journals and has a publication record totaling more than 140 scientific articles. He serves on the board of the Damon Runyon Cancer Research Foundation and the Walther Cancer Institute and on several committees for the American Association of Cancer Research and other leading cancer organizations.
Education: Dr. Gaynor received his MD degree from the University Of Texas Southwestern Medical School. He served his internship and residency in internal medicine at Parkland Memorial Hospital in Dallas, Texas. He completed a fellowship in hematology-oncology at the University of California at Los Angeles (UCLA) School of Medicine and then served on the faculty there. He received board certification in internal medicine, hematology and medical oncology.
Fabio Gratton is the founder and CEO of Sonic Health, a digital consultancy focused on helping life science companies and marketing agencies infuse innovation into their digital health initiatives. Furthermore, Fabio is co-founder and CEO of Vocalize, a new tech startup out of Southern California that is focused on adding a voice layer to the world through innovative mobile technologies. Vocalize has created a new, industry-first platform, Truvio, that connects the voice of 65,000 consumer health opinion leaders directly to companies who want to hear what they think. He is also Chief Alchemist at a new digital health incubator he founded called Alchemy Factory, where he will be focused on helping health tech startups accelerate and commercialize their products.
Previous experience: Fabio founded one of the leading digital agencies in the US, Ignite Health, that went on to be acquired by inVentiv Health in 2007. Fabio stayed on to operate as Chief Innovation Officer through 2013. He currently continues to consult with the agency that he helped to create, now Palio+Ignite, in the capacity of Chief Alchemist. During his 14-year career in digital marketing Fabio has worked with some of the largest pharmaceutical and medical device companies in the world– including Medtronic, Merck, Pfizer, Roche, Genentech, Bausch & Lomb, and Abbott.
Other experiences: Fabio has helped create a ground-breaking, award-winning animated series for people living with HIV, created the first simstyle game for children living with diabetes, and led the unprecedented FDASM movement — an online twitter-fueled initiative that brought together agencies and pharmaceutical companies to discuss, debate, and share ideas regarding the impending FDA guidelines on the use of the Internet and social media.
Dr. William N. Kelley, M.D. is currently Professor of Medicine, Biochemistry and Biophysics at the University of Pennsylvania School of Medicine since February 2000. He has had many roles including, President of the American Society for Clinical Investigation, President of the American College of Rheumatology. Furthermore, he has served as Chief Executive Officer of the University of Pennsylvania Medical Center and Health System, Dean of the School of Medicine. Dr. Kelley served as Executive Vice President of the Pennsylvania University from 1989 to February 2000.
Prior to Upenn, he was the John G. Searle Professor and Chairman of the Department of Internal Medicine and Professor of Biological Chemistry at the University of Michigan in Ann Arbor from 1975 to 1989. Prior to 1975, he was Professor of Medicine and Chief of the Division of Rheumatic and Genetic Diseases at Duke University Medical Center. His work has involved experimental models of gene therapy.
Other experiences include: Director of GenVec Inc. since June 2002. He served as a Director of Merck & Co. Inc. from 1992 until May 22, 2012. Dr. Kelley served as a Director of Advanced Bio-Surfaces Inc., since 2001. He served as a Director of Beckman Coulter Inc. from 1994 to June 20, 2011. Other roles include Trustee of The Merck Company Foundation. Dr. Kelley serves as member of the Board for Trustees at Emory University and the Emory Health Care System.
Dr. Kelley is a Member of the Institute of Medicine of the National Academy of Sciences. He is a Fellow of the American Academy of Arts and Sciences, a Member of the Association of American Physicians and the American Philosophical Society, and a Master of the American College of Physicians.
Dr. Jason Mills, MD, PhD joined the Division of Gastroenterology, Department of Medicine in January, 2011 at Washington University. His appointments are in Pathology & Immunology as well as Developmental Biology. Dr. Mills graduated summa cum laude from Washington University as an undergraduate, where he was the Moog scholar in humanities and sciences, majoring in Russian and biology. He received his MD and PhD from the University of Pennsylvania, where he studied the role of the cytoskeleton in apoptosis. He returned to Washington University for his residency in Anatomical Pathology and a postdoctoral fellowship in Jeff Gordon’s lab, where he studied the genomics of gastric epithelial differentiation. He set up his own lab at Washington University in 2004, where he studies epithelial differentiation in the GI tract during development, injury/inflammation, and carcinogenesis.
Other awards and honors for Dr. Mills: He is the recipient of an American Cancer Society Research Scholar Award, as well as the 2010 Funderburg Award in Gastric Biology Related to Cancer and the 2010 Washington University Faculty Mentor Award. He is an Associate Editor for the journal Physiological Genomics, and also serves on the Editorial Board of Gastroenterology, Digestive Diseases and Sciences, and The American Journal of Physiology GI Liver. Dr. Mills has published over 50 articles and books, which have been cited over 1500 times.
Dr. Roger Pomerantz, MD is on the Board of Directors for Seres Health. He was formerly Worldwide Head of Licensing & Acquisitions, Senior Vice President at Merck & Co., Inc. where he was involved in all licensing and acquisitions at Merck Research Laboratories, including external research, out-licensing regional deals and academic alliances. Previously, he has served as Senior Vice President and Global Franchise Head of Infectious Diseases at Merck. Before Merck, Dr. Pomerantz was Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals, where he was responsible for all anti-infective agents worldwide. He joined Johnson & Johnson in 2005 as President of Tibotec Pharmaceuticals, Inc.
Education: Dr. Pomerantz received his B.A. in Biochemistry at the Johns Hopkins University and his M.D. at the Johns Hopkins School of Medicine. He completed his Internal Medicine internship and residency training, and his subspecialty clinical and research training in Infectious Diseases and Virology at the Massachusetts General Hospital (M.G.H.) of the Harvard Medical School and was selected and served as the Chief Medical Resident at M.G.H. His post-doctoral research training in Molecular Retrovirology was obtained at both the Harvard Medical School and the Whitehead Institute of the Massachusetts Institute of Technology, in the laboratory of Nobel Laureate, Dr. David Baltimore. Following Dr. Pomerantz became Professor of Medicine, Biochemistry and Molecular Pharmacology, Chief of Infectious Diseases, and the Founding Director and Chair of the Institute for Human Virology and Biodefense at the Thomas Jefferson University and Medical School. He has developed seven approved infectious disease drugs in important diseases including HIV, HCV, and tuberculosis.